S100A1 Gene Therapy Preserves in Vivo Cardiac Function after Myocardial Infarction
Open Access
- 1 December 2005
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 12 (6) , 1120-1129
- https://doi.org/10.1016/j.ymthe.2005.08.002
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- S100A1 increases the gain of excitation–contraction coupling in isolated rabbit ventricular cardiomyocytesJournal of Molecular and Cellular Cardiology, 2005
- Vascular Endothelial Growth Factor Activation of Sterol Regulatory Element Binding ProteinCirculation Research, 2004
- Genetic manipulation of myocardial ?-adrenergic receptor activation and desensitizationJournal of Molecular and Cellular Cardiology, 2004
- S100A1 gene transfer: a strategy to strengthen engineered cardiac graftsThe Journal of Gene Medicine, 2004
- The C Terminus (Amino Acids 75–94) and the Linker Region (Amino Acids 42–54) of the Ca2+-binding Protein S100A1 Differentially Enhance Sarcoplasmic Ca2+ Release in Murine Skinned Skeletal Muscle FibersPublished by Elsevier ,2003
- Ventricular remodeling without cellular contractile dysfunctionJournal of Cardiac Failure, 2002
- Ventricular remodeling in heart failureJournal of Cardiac Failure, 2002
- Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene deliveryJournal of Clinical Investigation, 1999
- Correlation between cardiac remodelling, function, and myocardial contractility in rat hearts 5 weeks after myocardial infarctionCanadian Journal of Physiology and Pharmacology, 1998
- Altered expression of the Ca2+-binding protein S100A1 in human cardiomyopathyBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1996